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Abstract
Background
Automated digital microscopy has the potential to improve the diagnosis of tuberculosis
(TB), particularly in settings where molecular testing is too expensive to perform routinely.
The cost-effectiveness of TB diagnostic algorithms using automated digital microscopy
remains uncertain.
Methods
Using data from a demonstration study of an automated digital microscopy system (TBDx,
Applied Visual Systems, Inc.), we performed an economic evaluation of TB diagnosis in
South Africa from the health system perspective. The primary outcome was the incremental
cost per new TB diagnosis made. We considered costs and effectiveness of different algo-
rithms for automated digital microscopy, including as a stand-alone test and with confirma-
tion of positive results with Xpert MTB/RIF (‘Xpert’, Cepheid, Inc.). Results were compared
against both manual microscopy and universal Xpert testing.
Results
In settings willing to pay $2000 per incremental TB diagnosis, universal Xpert was the pre-
ferred strategy. However, where resources were not sufficient to support universal Xpert,
and a testing volume of at least 30 specimens per day could be ensured, automated digital
microscopy with Xpert confirmation of low-positive results could facilitate the diagnosis of
79–84% of all Xpert-positive TB cases, at 50–60% of the total cost. The cost-effectiveness
of this strategy was $1280 per incremental TB diagnosis (95% uncertainty range, UR: $340-
$3440) in the base case, but improved under conditions likely reflective of many settings in
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sub-Saharan Africa: $677 per diagnosis (95% UR: $450-$935) when sensitivity of manual
smear microscopy was lowered to 0.5, and $956 per diagnosis (95% UR: $40-$2910) when
the prevalence of multidrug-resistant TB was lowered to 1%.
Conclusions
Although universal Xpert testing is the preferred algorithm for TB diagnosis when resources
are sufficient, automated digital microscopy can identify the majority of cases and halve the
cost of diagnosis and treatment when resources are more scarce and multidrug-resistant
TB is not common.
Background
Every year, an estimated 3.6 million individuals develop active tuberculosis (TB) yet are not
notified to public health authorities[1]. Improved diagnostic testing for TB is likely to be criti-
cal for reaching this “missing 3 million”[2, 3]. Current testing algorithms largely depend either
on sputum smear microscopy—a test with variable sensitivity that depends on operator skill
and such variables as microscopist time constraints[4]–or Xpert MTB/RIF (Cepheid, Inc.; Sun-
nyvale, CA, USA), a molecular test with higher sensitivity and the ability to detect rifampin
resistance[5, 6], but that can cost over ten times more per test than sputum smear[3, 7]. For set-
tings in which high-quality sputum smear microscopy cannot be performed, but performing
Xpert MTB/RIF on all patients with symptoms of TB may be very expensive (including settings
of systematic screening for TB), automated digital microscopy offers an attractive alternative
[8]. Automated visualization algorithms can facilitate high-quality sputum smear microscopy
that is not user-dependent in interpretation; an example of an automated microscopy system
that was recently validated is the TBDx system (Applied Visual Sciences, Leesburg, VA, USA)
[9]. This system uses patented software and a high-specification camera to identify acid fast
bacilli, thereby reducing subjectivity in results and potentially improving performance. In a
prospective single-center study at the National Tuberculosis Reference Laboratory in Johan-
nesburg, South Africa, TBDx was shown to have 0.78 sensitivity for culture-proven TB, and
when positive results were confirmed by Xpert MTB/RIF, the specificity of the algorithm was
estimated at 0.998[9]. However, whether TBDx or a similar automated microscopy system
could be cost-effective in high-burden settings remains uncertain. Thus, we used data from this
study to perform an economic evaluation of automated digital microscopy for active TB in a
representative African reference lab setting.
Methods
Overview
Like most automated microscopy systems, TBDx provides results at different levels of certainty;
in the case of TBDx, as reported in the published demonstration study [9], there are four rele-
vant result levels: negative (no acid-fast bacilli [AFB] detected), “scanty 1” (<1 AFB per 300
high-power fields), “low positive” (2–9 AFB per 300 high-power fields), and “high positive”
(10 AFB per 300 high-power fields). We used data on these TBDx results, alone and in com-
bination with Xpert MTB/RIF, as performed in 1009 South African adults with clinical suspi-
cion of TB, to construct a model of the effectiveness of such testing in a hypothetical
population of 10,000 people having characteristics of the source population. In addition to
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diagnostic consequences, we estimated the costs of TB testing and treatment from a health sys-
tem perspective. The original study was approved by the Faculty of Health Sciences Research
Ethics Committee at the University of Pretoria; no additional ethical approval was required for
this non-human subjects analysis.
We evaluated the costs and effectiveness of a series of alternative algorithms: (1) sputum
smear microscopy alone; (2) TBDx automated microscopy alone; (3) TBDx automated micros-
copy, with confirmation of low positive results by Xpert MTB/RIF; (4) TBDx automated
microscopy, with confirmation of all positive results by Xpert MTB/RIF; and (5) Xpert MTB/
RIF performed on all specimens. For each algorithm including automated microscopy, we con-
sidered scenarios in which “scanty 1” results were treated as either negative or low positive.
Under each scenario, we projected the total number of patients with culture-confirmed TB
who would be treated, the number of false-positive diagnoses that would be made, and the total
costs from a health system perspective. For purposes of appropriate comparison (to scenarios
in which treatment of drug-resistant TB would otherwise not be considered), we also consid-
ered options in which drug susceptibility testing was performed for all individuals before initia-
tion of TB treatment. We also considered three alternative scenarios of treatment volume: a
“high-volume” scenario in which 100 individuals were evaluated per day, a “moderate-volume”
scenario in which 30 individuals were evaluated per day and a “low-volume” scenario in which
10 individuals were evaluated per day. Our primary outcome was the incremental cost per
incremental true-positive diagnosis made, relative to sputum smear microscopy alone as the
reference scenario.
Diagnostic costs
All costs were valued in 2015 US dollars, with conversion from South African rand into US dol-
lars using the historical exchange rate and inflation to year 2015 using the South African gross
domestic product (GDP) deflator[10]. Unit costs were developed for sputum smear, TBDx
automated microscopy, and Xpert MTB/RIF using estimates from the literature in an “ingredi-
ents” approach as shown in Table 1. Overheads (including building space) and utilities were
estimated from other published evaluations of sputum smear microscopy and Xpert MTB/RIF
in South Africa, conservatively assuming that allocations for TBDx-enhanced microscopy
would be similar to Xpert MTB/RIF (and thus higher than for microscopy) and also including
an annual cost for quality assurance and training, the allocation of which to each type of diag-
nostic modality was assumed to be $400[11–13].
Costs of capital equipment (e.g., microscopes and Xpert systems) were also taken from the
literature and annualized using a 3% annual discount rate and an expected useful life of five
years (Xpert) or ten years (microscope and camera)[14, 15]. Costs of required hardware and
software licensing for TBDx were valued in consultation with experts from Applied Visual Sys-
tems, Inc.–who provided estimates of cost without any input as to the use of those estimates in
the economic model. These estimates included: (a) a licensing fee of $2 per slide in a high-vol-
ume setting or $15,000 per year in low and moderate-volume setting; (b) combined equipment
costs of slide loader-fitted microscope and camera of $27,000 for a low and moderate-through-
put loader and $47,000 for a high-throughput loader; (c) $3,600 in installation and shipping
costs; (d) $1,000 for a computer and printer (also applied to the Xpert MTB/RIF); and (e)
annual maintenance and warranty at 10% of total equipment costs (also applied to Xpert and
fluorescence microscopes).
Personnel costs were estimated assuming an hourly wage of $5.13 for a general laboratory
technician and $6.83 for a skilled microscopist[11, 12, 16]. We assumed that all procedures
related to Xpert specimen preparation, loading, and results reporting would take 15 minutes
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per test (run on-demand), versus five minutes per slide for sputum smear (where individual
smears can be batched), plus an additional seven minutes per slide for manual reading. Con-
sumables were estimated at $0.10 for sputum smear (including TBDx) and $9.98 for Xpert
MTB/RIF (the current cost of an Xpert cartridge)[13, 15, 17, 18], with procurement and ship-
ping costs estimated at 10% of the unit price.
Treatment costs
We estimated the cost of TB treatment according to the cost of first-line and second-line drugs
as well as necessary outpatient follow-up. We did not attempt to estimate downstream conse-
quences after initiation of treatment; thus, all people diagnosed with TB were assigned a treat-
ment cost equivalent to drugs and outpatient visits for six months (if drug-susceptible) or
twenty months (if multidrug-resistant, MDR), and all people not diagnosed with TB were
treated as false-negative or true-negative, without attempting to capture future attempts at
diagnosis or empiric treatment. We assumed that culture-based drug susceptibility testing
would be performed prior to any initiation of MDR-TB therapy, and we included the costs
thereof. We assumed a high proportion of MDR-TB (5% of all cases), as might be reflective of
testing performed at a national referral center. Costs of diagnosis with standard sputum smear
microscopy and Xpert MTB/RIF, as well as other component costs of automated microscopy
(e.g., staff costs, overhead costs, DST) were estimated from the literature[12, 13, 16, 19, 20]. A
full listing of model parameters is given in Table 2.
Sensitivity analyses
We performed one-way sensitivity analysis on all model parameters across reasonable ranges
as shown in Table 2. In addition, we also performed scenario analyses for high- and low-vol-
ume settings (as above) and at different assumed levels of MDR-TB prevalence. In addition, we
performed a probabilistic uncertainty analysis in which all parameters were simultaneously
varied over the ranges shown in Table 2 (and by +/-25% of base value for each cost component
not shown in Table 2). Each parameter range was defined as a beta distribution with an alpha
(shape) parameter of 4. The results of this analysis are reported as 95% uncertainty ranges
(95% UR’s), bounded by the 2.5th and 97.5th percentiles of the resulting simulations.
Table 1. Unit Costs of Diagnostic Tests for Tuberculosis in South Africa (2015 US$).
Cost components Sputum Smear Microscopy Automated Digital Microscopy Xpert MTB/RIF
100
samples/d
30
samples/d
10
samples/d
100
samples/d
30
samples/d
10
samples/d
100
samples/d
30
samples/d
10
samples/d
Utilities and
overheads
0.08 0.14 0.31 0.10 0.17 0.40 0.14 0.26 0.59
Equipment* 0.01 0.02 0.06 0.65 1.57 4.70 1.92 2.33 3.67
Staff 1.37 1.37 1.37 0.47 0.47 0.47 1.32 1.32 1.32
Licensing 0.00 0.00 0.00 2.00 2.10 6.25 0.00 0.00 0.00
Consumables** 0.12 0.12 0.12 0.12 0.12 0.12 11.48 11.48 11.48
Total $1.59 $1.65 $2.07 $3.35 $4.43 $12.14 $14.45 $15.39 $16.94
*inclusive of shipping and installation cost, annual warranty, repair and maintenance cost;
** Inclusive of shipping and distribution cost
doi:10.1371/journal.pone.0157554.t001
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Results
Impact of volume on cost of automated microscopy
In a low-volume setting processing 10 specimens per day, the unit cost of automated digital
microscopy was nearly that of Xpert MTB/RIF (Table 1), due to the relatively high costs of
both equipment and annual software licensing for TBDx. By contrast, in both moderate (30
specimens/day) and high-volume (100 specimens/day) settings, the per-test cost of automated
microscopy was about one-third that of Xpert MTB/RIF. Given the relatively low likelihood
that automated microscopy would be performed instead of Xpert MTB/RIF if the unit costs of
testing were similar, we focused subsequent analyses on the high-volume setting.
Costs and consequences of automated digital microscopy
Table 3 shows the costs and consequences of various testing algorithms for active TB that
incorporate automated digital microscopy. Using automated microscopy as a standalone test
(i.e., no confirmation of positive results by Xpert MTB/RIF) resulted in more false-positive
diagnoses than incremental true-positive diagnoses. However, if automated microscopy were
used as a triage test, with low-positive results confirmed by Xpert MTB/RIF and high-positive
results proceeding to treatment, 79–84% of all individuals with Xpert-positive TB could be
diagnosed (true TB diagnoses made), at 50–60% of the cost (total diagnostic cost plus total
treatment cost). This strategy had a favorable incremental cost-effectiveness ratio of $1,280 per
TB diagnosis made (95% uncertainty range, UR: $340-$3440), relative to manual sputum
Table 2. Model Parameters.
Parameter Value Sensitivity range Reference
Proportion of patients with active TB 0.108 0.05–0.2 [1, 9]
Proportion of TB that is resistant to rifampin 0.09 0.02–0.2 [1, 19]
Proportion of TB that is multi-drug resistant 0.03 0.01–0.07
Sensitivity for culture-conﬁrmed TB: [9]
Sputum smear microscopy 0.68 0.4–0.68
TBDx (any positive) 0.80 0.7–0.9
TBDx (>1 AFB/300 ﬁelds) 0.73 0.6–0.85
TBDx (high positive) 0.62 0.55–0.7
Xpert MTB/RIF (TBDx +) 0.97 0.95–1.0
Xpert MTB/RIF (all TB) 0.91 0.8–1.0
Speciﬁcity: [9]
Sputum smear microscopy 0.992 0.98–1.0
TBDx (any positive) 0.79 0.7–0.9
TBDx (>1 AFB/300 ﬁelds) 0.96 0.92–0.98
TBDx (high positive) 0.998 0.99–1.0
Xpert MTB/RIF (TBDx +) 0.97 0.95–1.0
Xpert MTB/RIF (all TB) 0.990 0.98–1.0
Cost to treat one patient [3, 13, 16, 19, 20, 29]
Drug-susceptible TB $506 $300-$700
Drug-resistant TB $3660 $2000-$10,000
Daily capacity Assumption
Fluorescence microscope 50
High-throughput TBDx >100
Xpert MTB/RIF(4-module system) 16 [15]
doi:10.1371/journal.pone.0157554.t002
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smear microscopy with sensitivity of 0.68 (versus 0.73 for TBDx). If manual sputum smear had
a sensitivity of 0.5 rather than 0.68 (as observed in the TBDx demonstration study), this auto-
mated microscopy strategy would cost $677 per incremental TB diagnosis (95% UR: $450-
$935), relative to manual smear. If the prevalence of MDR-TB was lowered to 1% of all sam-
ples, the cost of this algorithm fell to $956 per diagnosis (95% UR: $40-$2910). The corre-
sponding cost-effectiveness frontier (Fig 1) demonstrates that this strategy would be preferred
where resources are insufficient for universal Xpert MTB/RIF, or the willingness to pay for an
incremental TB diagnosis falls between $1,280 ($677 if sensitivity of manual smear is 0.5) and
$1,927.
Sensitivity and scenario analyses
Assuming that both the specificity of manual sputum smear microscopy and the volume of
testing is high, three additional parameters were strong drivers of the incremental cost-effec-
tiveness of automated digital microscopy (Fig 2): the prevalence of TB, the prevalence of
MDR-TB, and the sensitivity of manual microscopy. In settings where the sensitivity of manual
microscopy is poor, the incremental cost-effectiveness of TBDx with Xpert confirmation of all
positive results began to approach that of universal Xpert (Table 3). This strategy allows for
78–83% of all Xpert-positive TB to be diagnosed, with all drug-resistant TB also treated. Under
most situations tested in sensitivity analysis, the algorithm that provided the most TB diagno-
ses per dollar spent (incremental to manual microscopy) was TBDx, with Xpert confirmation
of low-positive results, and counting “Scanty 1” results as negative.
Discussion
This economic evaluation provides insight as to the potential role of automated digital micros-
copy in the diagnosis of adult pulmonary tuberculosis. Specifically, in settings where universal
Xpert MTB/RIF is affordable, and health systems are willing to pay at least $1927 per incremental
Table 3. Cost-Effectiveness of Different TB Diagnostic Algorithms Performed on 1000 South African Adults in a High-Volume Setting with 5%
Prevalence of MDR TB.
Algorithm Diagnostic costs Treatment costs TB
treatments
(of 108 with
true TB)
False-positive treatments Incremental
cost per true TB
diagnosis
(relative to
manual smear)
Total Incr. Total Incr. Total Incr.
Sputum smear (manual)
Sensitivity 0.68 $1,590 REF $41,300 REF 73.5 REF 8 REF -
Sensitivity 0.5 $1,590 - $31,400 - 54 - 8 - REF
Automated microscopy
Scanty 1 = low positive
Microscopy only (stand-alone) $3,350 $1,760 $150,600 $109,400 86.4 12.9 211 $8,570 $3,730
Xpert to conﬁrm low positive $6,370 $4,780 $51,900 $10,600 84.2 10.8 12 $1,430 $835
Xpert to conﬁrm any positive $7,550 $5,960 $61,600 $20,400 83.1 9.7 11 $2,710 $1,240
Scanty 1 = negative
Microscopy only (stand-alone) $3,350 $1,760 $61,400 $20,100 78.8 5.4 42 $4,050 $1,280
Xpert to conﬁrm low positive $4,090 $2,500 $45,700 $4,420 78.9 5.4 7 $1,280 $675
Xpert to conﬁrm any positive $5,270 $3,680 $55,400 $14,100 77.8 4.3 6 $4,130 $1,160
Xpert MTB/RIF for all $14,700 $13,200 $72,600 $31,400 99.4 25.9 10 $1,720 $1,200
doi:10.1371/journal.pone.0157554.t003
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TB diagnosis made, universal Xpert is generally preferred. If an incremental microbiologically-
confirmed TB diagnosis can lead to one year of additional life (or disability-adjusted life year
averted), this willingness-to-pay threshold would be considered highly cost-effective by tradi-
tional criteria in most high-burden countries[21, 22]. This finding is consistent with prior eco-
nomic evaluations suggesting that Xpert is likely to be highly cost-effective relative to sputum
smear microscopy where the level of empiric TB diagnosis is low[7, 20]. However, in many set-
tings, universal Xpert MTB/RIF is not an affordable option[13], in part owing to recurring main-
tenance and calibration costs. In these cases, and when specimens can be processed at moderate-
to-high volume, automated digital microscopy (with confirmation of positive results by Xpert)
can improve the yield of manual microscopy, and at an incremental cost-effectiveness ratio that
is favorable relative to universal Xpert. The strategy that appears to optimize cost-effectiveness in
most settings is Xpert confirmation of low-positive results only, taking high-positive results as a
direct indication for treatment.
Prior analyses have evaluated the potential cost-effectiveness of hypothetical “triage” tests
for active TB, suggesting that such tests could be cost-effective under certain conditions[23].
This analysis is among the first to evaluate a novel diagnostic test for TB that could be used for
purposes of triage. Such tests are designed to provide the majority of the benefit of using a
more sensitive confirmatory test (e.g., Xpert MTB/RIF), but at a reduced cost—and ideally a
more favorable cost-effectiveness ratio, such that it is preferable to perform the triage test on
the full population rather than the confirmatory test on part of it. This economic evaluation
Fig 1. Cost-Effectiveness Frontier. The number of true-positive microbiological diagnoses for each algorithm is shown on the x-
axis and the corresponding costs on the y-axis, such that the slope of any line is the incremental cost-effectiveness ratio between
two algorithms. Algorithms appearing further to the right are more effective, and those appearing higher on the y-axis are more
expensive. The frontier of cost-effective options is shown as a solid dark line, with incremental cost-effectiveness ratios (in units of
cost per true-positive TB treatment) shown for each comparison along this frontier. In a setting of constrained resources, automated
digital microscopy with low-positive results confirmed by Xpert MTB/RIF would be the first selected strategy beyond sputum smear
microscopy alone, followed by Xpert MTB/RIF for all specimens, where resources are sufficient. If one incremental microbiological
diagnosis could avert as few as 0.2 disability-adjusted life years, all strategies along the cost-effectiveness frontier would be cost-
effective, at a willingness-to-pay threshold equal to South Africa’s per-capita annual gross national income (GNI). Sc1 = “scanty 1”
result; pos = positive; neg = negative; sens. = sensitivity.
doi:10.1371/journal.pone.0157554.g001
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demonstrates precisely this result, specifically that automated digital microscopy can reduce
the overall costs of diagnostic testing substantially, and be performed at a cost-effectiveness
ratio that is generally favorable to that of universal Xpert.
As shown in our sensitivity analysis, automated microscopy is particularly attractive in set-
tings where manual microscopy cannot be performed with consistent quality. For TBDx as a
specific example of automated microscopy, the preferred algorithm is one in which high-posi-
tive results lead directly to treatment, low-positive results are confirmed with Xpert (or other
more accurate confirmatory test), and inconclusive results (i.e., 1 AFB per 300 fields) are
treated as negative. Unless the cost of licensing and equipment can be brought down in the
future, TBDx is likely to be too expensive on a per-test basis to scale up in low-volume settings
that do not perform substantially more than 10 sputum evaluations for TB each day.
Two elements of automated digital microscopy performance bear mention in this analysis.
Automated digital microscopy was performed on concentrated sputum specimens, which may
increase the sensitivity of both manual and automated microscopy[24], though perhaps less so
in those infected with HIV[25]. Customized slides and marking of the inoculation area for
camera guidance were also critical to test performance; though not major contributors to cost,
these required elements may limit the ability to perform automated digital microscopy in some
settings. Furthermore, while slides are still manually prepared, the automated algorithm does
not assess sputum quality.
As with any modeling analysis, this evaluation has certain limitations. Parameter values
were drawn from the literature and, in some cases, required assumptions based on expert opin-
ion. Nevertheless, our results were robust to most sensitivity analyses, and particularly sur-
rounding those parameter values that were most uncertain. We did not attempt to incorporate
downstream effectiveness measures, including the health benefits of making TB diagnoses nor
the costs and effectiveness of HIV therapy, which is a major driver of the economics of TB
diagnosis in HIV-endemic settings[26]. Our ability to compare automated microscopy to
health interventions other than TB diagnostic assays is therefore limited. Nevertheless, we are
able to demonstrate that the cost-effectiveness of automated microscopy is likely similar (if not
superior) to that of Xpert MTB/RIF, which has been modeled in such fashion[7]. We limited
Fig 2. One-Way Sensitivity Analysis. Primary drivers of cost-effectiveness in one-way sensitivity analysis. All parameters in
Tables 1 and 2 were varied; only those parameters that resulted in a change of +/-$200 in the incremental cost-effectiveness
ratio are shown. Blue bars correspond to the incremental cost-effectiveness of automated microscopy by TBDx relative to
manual smear microscopy, at the low value of the specified parameter range. Red bars correspond to the incremental cost-
effectiveness at the high value of that range, holding all other parameter values constant.
doi:10.1371/journal.pone.0157554.g002
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this analysis to the costs and consequences of microbiological diagnosis; in reality, ancillary
diagnostic testing (e.g., with chest X-ray) and empiric treatment may have major impact on
patient outcomes[27, 28]. Our results should therefore not be interpreted as reflective of the
entire process of TB diagnosis and treatment, but rather only of the costs and consequences of
diagnosis and treatment based on microbiological confirmation.
In summary, this economic evaluation suggests that automated digital microscopy can serve
as a cost-effective alternative to Xpert MTB/RIF when specimens can be processed at high vol-
ume and universal Xpert is unaffordable. The algorithm most likely to be cost-effective is one
in which high-positive results on automated microscopy result in referral for treatment, low-
positive results are confirmed with Xpert, and inconclusive results are treated as negative. Fur-
ther studies should evaluate the effectiveness (ideally with linkage to empiric costs) of auto-
mated digital microscopy in a variety of real-world settings. As the armamentarium of
diagnostic options for TB continues to expand, it is important to optimize the use of each test
in such a way that constrained resources are put to their best use. By reducing the costs of
Xpert MTB/RIF testing while still providing the majority of the benefits (in terms of TB diag-
noses), automated digital microscopy has the potential to fill an important niche in the TB
diagnostic landscape.
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